BRAINSTORM CELL THERAPEUTICS (BCLI)
US10501E2019 - Common Stock
BrainStorm Cell Therapeutics Announces Management Changes as Company Plans Registrational Phase 3b Trial of NurOwn
/PRNewswire/ -- BrainStorm Cell Therapeutics Inc. (NASDAQ: BCLI), a leading developer of adult stem cell therapeutics for neurodegenerative diseases, today...
BrainStorm Cell Therapeutics Regains Compliance with NASDAQ Minimum Market Value Rule
/PRNewswire/ -- BrainStorm Cell Therapeutics Inc. (NASDAQ: BCLI, "the Company"), a leading developer of cellular therapies for neurodegenerative diseases,...
BrainStorm Cell Therapeutics Announces Peer-reviewed Publication of Biomarker Data from NurOwn's® Phase 3 Clinical Trial in ALS
/PRNewswire/ -- BrainStorm Cell Therapeutics Inc. (NASDAQ: BCLI), a leading developer of cellular therapies for neurodegenerative diseases, today announced the...
Top movers in Tuesday's after hours session
Get insights into the top gainers and losers of Tuesday's after-hours session.
Today’s Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on Tuesday
Pre-market stock movers are worth checking out as we get into all of the hottest news investors need to know about on Tuesday morning!
BrainStorm Cell Therapeutics Announces Agreement with FDA on a Special Protocol Assessment (SPA) for Phase 3b Trial in ALS
/PRNewswire/ -- BrainStorm Cell Therapeutics Inc. (NASDAQ: BCLI), a leading developer of adult stem cell therapeutics for neurodegenerative diseases, today...
Get insights into the top gainers and losers of Monday's after-hours session.
Get insights into the top gainers and losers of Monday's after-hours session.
BrainStorm Cell Therapeutics to Provide Update on NurOwn Program
/PRNewswire/ -- BrainStorm Cell Therapeutics Inc. (NASDAQ: BCLI), a leading developer of cellular therapies for neurodegenerative diseases, announced today...
BCLI Stock Earnings: Brainstorm Cell Beats EPS for Q4 2023
BCLI stock results show that Brainstorm Cell beat analyst estimates for earnings per share the fourth quarter of 2023.
BrainStorm Cell Therapeutics Announces Full Year 2023 Financial Results and Provides Corporate Update
/PRNewswire/ -- BrainStorm Cell Therapeutics Inc. (NASDAQ: BCLI), a leading developer of adult stem cell therapeutics for neurodegenerative diseases, today...
BrainStorm Cell Therapeutics to Unveil Phase 3b NurOwn® Trial Design at MDA Clinical and Scientific Conference
/PRNewswire/ -- BrainStorm Cell Therapeutics Inc. (NASDAQ: BCLI), a leading developer of adult stem cell therapeutics for neurodegenerative diseases, today...
BrainStorm submits SPA request to FDA for Phase 3 study design (NASDAQ:BCLI)
BrainStorm Cell Therapeutics (BCLI) said it has submitted a Special Protocol Assessment request to the FDA for a Phase 3b study of its cell therapy NurOwn in the treatment of ALS.
BrainStorm Cell Therapeutics Submits Special Protocol Assessment (SPA) Request to FDA for Phase 3b Trial of NurOwn® in ALS
/PRNewswire/ -- BrainStorm Cell Therapeutics Inc. (NASDAQ: BCLI), a leading developer of adult stem cell therapeutics for neurodegenerative diseases, today...
BrainStorm Cell Therapeutics to Present at European Life Sciences CEO Forum
/PRNewswire/ -- BrainStorm Cell Therapeutics Inc. (NASDAQ: BCLI), a leading developer of adult stem cell therapeutics for neurodegenerative diseases, today...
BCLI DEADLINE: ROSEN, A LEADING LAW FIRM, Encourages Brainstorm Cell Therapeutics Inc. Investors with Losses in Excess of $100K to Secure Counsel Before Important Deadline in Securities Class Action Commenced by the Firm - BCLI
Search for the latest press releases from publicly traded companies, private corporations, non-profits and other public sector organizations.
SHAREHOLDER ALERT: Levi & Korsinsky Notifies Brainstorm Cell Therapeutics Inc.(BCLI) Investors of a Class Action Lawsuit and Upcoming Deadline
/PRNewswire/ -- Levi & Korsinsky, LLP notifies investors in Brainstorm Cell Therapeutics Inc. ("Brainstorm Cell" or the "Company") (NASDAQ: BCLI) of a class...
BCLI FINAL DEADLINE TUESDAY: ROSEN, GLOBAL INVESTOR COUNSEL, Encourages Brainstorm Cell Therapeutics Inc. Investors with Losses in Excess of $500K to Secure Counsel Before Important January 2 Deadline in Securities Class Action Filed by the Firm - BCLI
/PRNewswire/ -- WHY: Rosen Law Firm, a global investor rights law firm, reminds purchasers of the securities of Brainstorm Cell Therapeutics Inc. (NASDAQ:...
BCLI FINAL DEADLINE ALERT: ROSEN, THE FIRST FILING FIRM, Encourages Brainstorm Cell Therapeutics Inc. Investors with Losses in Excess of $500K to Secure Counsel Before Important January 2 Deadline in Securities Class Action Initiated by the Firm - BCLI
Search for the latest press releases from publicly traded companies, private corporations, non-profits and other public sector organizations.
SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims on Behalf of Investors of Brainstorm Cell Therapeutics Inc. - BCLI
/PRNewswire/ -- Pomerantz LLP is investigating claims on behalf of investors of Brainstorm Cell Therapeutics Inc. ("Brainstorm" or the "Company") (NASDAQ:...
The Law Offices of Frank R. Cruz Reminds Investors of Looming Deadline in the Class Action Lawsuit Against Brainstorm Cell Therapeutics Inc. (BCLI)
BRAINSTORM INVESTOR DEADLINE APPROACHING: Securities Litigation Partner James (Josh) Wilson Encourages Investors Who Suffered Losses Exceeding $25,000 In Brainstorm To Contact Him Directly To Discuss Their Options
/PRNewswire/ -- Faruqi & Faruqi, LLP, a leading national securities law firm, is investigating potential claims against Brainstorm Cell Therapeutics Inc....
ROSEN, NATIONALLY REGARDED INVESTOR COUNSEL, Encourages Brainstorm Cell Therapeutics Inc. Investors with Losses to Secure Counsel Before Important January 2 Deadline in Securities Class Action First Filed by the Firm - BCLI
Search for the latest press releases from publicly traded companies, private corporations, non-profits and other public sector organizations.
